
    
      IPX066 is intended for chronic treatment of motor symptoms for all stages of PD. This study
      is designed to enroll subjects who have successfully completed one of the following studies
      of IPX066:

        -  IPX066-B08-05 (A Placebo-Controlled Study to Evaluate the Safety and Efficacy of IPX066
           in Subjects with Parkinson's Disease)

        -  IPX066-B08-11 (A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to
           Standard Carbidopa - Levodopa)

        -  IPX066-B09-02 (A Study to Evaluate the Safety and Efficacy of IPX066 in Advanced
           Parkinson's Disease)

      All participants will be given IPX066 for 9 months.
    
  